Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.
INTRODUCTION
The vast majority of children being diagnosed with AML are treated according to prospectively designed study protocols within the AML-BFM study network. Two main concepts of postremission consolidation therapy have been the topic of vivid debate, namely conventional chemotherapy vs hematopoietic SCT (HSCT). The prospective multi-center AML-BFM 98 trial aimed to address this question by means of biological randomization. Based on the availability of an HLA-matched sibling donor, children in first CR (CR1) either underwent HSCT or received chemotherapy alone after double induction and consolidation therapy. Results from this trial neither showed a significantly different 5-year disease-free survival (49% vs 45%) nor a superior OS (68% vs 57%). However, treatment-related late sequelae were more frequently observed in children after HSCT. 1 Very similar results were independently retrieved from the British MRC AML 10 trial. 2 Based on these findings, HSCT in CR1 was abandoned in the subsequent AML-BFM trial since 2006 and recommended as a rescue option for children after first relapse only.
Despite considerable improvements, the prognosis of children suffering from AML relapse remains much less favorable. In the case of relapse the prospects of cure remain dismal with alternate chemotherapy. [3] [4] [5] Data from the most recent international BFM relapse show that only 72% of children achieve a second CR. Five-year OS was 32%. 6 HSCT is currently considered to be the most promising therapeutic element in second remission (CR2). Germany has about 82 million inhabitants out of which 100 children are newly diagnosed with AML per year. Of those, 40 children will ultimately relapse. Based on these low numbers the need for a common BFM transplantation concept became evident. However, the launch of a common prospective and controlled BFM-HSCT trial took another 6 years and finally started to recruit patients in January 2010. In the meantime, there was a consensus within the AML-BFM study group to transplant children achieving CR2 from a matched related or unrelated donor after AML relapse using a triple alkylating preparative regimen consisting of BU, CY and melphalan (BuCyMel). Here, we retrospectively report on the results of this interphase study.
PATIENTS AND METHODS Patients
Pediatric AML patients after first relapse were included in this retrospective multicentre cohort analysis, if the following criteria were met: de novo AML, aged p21 years, registered in 'AML-BFM 98' or 'AML-BFM-2004' trials, relapses occurred between 01 January 1997 and 01 June 2010, and were mostly treated according the trial 'Relapsed AML 2001/01'. Some patients were treated as recommended by the International Registry 'Relapsed AML 2009' (5). Additionally, a CR2 had to be achieved and a preparatory regimen for HSCT consisting of BuCyMel was to be used. Sixty patients were identified in 31 German centers between November 2000 and February 2009. Patients with haploidentical donors or umbilical cord blood were excluded from this analysis.
Before being enrolled in the AML trials the patients and/or their guardians gave informed consent allowing retrospective data analysis.
Data source and collection
Data such as leukemia type, course of the disease and outcome including HSCT were documented for the AML-BFM upfront trials and were retrieved from the pediatric AML-BFM database. In some cases data on GVHD and outcome after HSCT needed to be verified retrospectively. The data were analyzed on behalf of the German pediatric AML-BFM study group.
Patients, donors and conditioning The patient and disease characteristics, as well as major outcome characteristics, are shown in Table 1 . Most patients and potential donors (2/3) underwent four-digit high-resolution typing for HLA class I (A, B, Cw) and II (DRB1 and DQB1). In cases of 9/10 or 10/10 allele-identity, donors were defined as matched donors. All others were classified as partially mismatched. All patients received a preparative regimen containing either the i.v. (weight adjusted, every 6 or 24 h) or in some cases the oral preparation of BU (every 6 h) from day-7 through day-4, CY (60 mg/kg on 2 consecutive days), and MEL (140 mg/m 2 as a single dose).
GVHD prophylaxis and therapy
CsA in combination with short-term MTX was used for GVHD prophylaxis in most cases (52/60). In 11/60 patients CsA was given with MTX only, the majority of patients (41/60) received additional antithymocyte globulin. Single-agent GVHD prophylaxis with CsA was done in 6/60 patients. For two patients who received a CD34-positive selected graft, antithymocyte globulin without CsA and MTX was given.
Definitions
Engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count 40.5 Â 10 9 /L. Failure to engraft by day þ 40 was considered as primary graft failure. Platelet engraftment was defined as the first of 7 consecutive days during which the platelet count exceeded 20 Â 10 9 /L without transfusion support. Acute GVHD (aGVHD) and chronic GVHD(cGVHD) were graded according to previously described criteria. 7, 8 Treatment-related mortality (TRM) was classified as mortality not associated with relapse. Relapse was defined as recurrence of 410% unequivocal leukemic BM blasts after documented CR and/or evidence of leukemic infiltration or recurrence at any site. Patient without microscopic evidence of disease were defined as being in first or second CR (CR1/2). OS was counted from the day of transplantation (day 0) until death from any cause.
Statistical methods
The specific baseline variables evaluated included age at diagnosis of relapse, sex, source of the graft and donor type (MSD, MUD, MMD).
Outcome variables included OS, EFS, cause of death, engraftment and aGVHD and cGVHD. Events were relapse, secondary malignant neoplasm or death from any cause. Patients lost to follow-up were censored at the time of withdrawal. For analyzing OS and EFS, the Kaplan-Meier method was used to estimate probabilities of survival. Differences in the distribution of individual parameters among patient subsets were analyzed using the w 2 test for categorized variables. The Cox proportional hazards model was used to obtain the estimates and the 95% confidence interval of the relative risk for prognostic factors. The two-tailored log-rank test was implemented for comparing survival curves. Cumulative incidence estimates were calculated for relapses, TRM and GVHD with deaths as competing events. If not otherwise specified, data are given as median with range (x;y). All P-values are two-sided and were considered significant when o0.05. Statistical analyses were conducted using the SAS program (Version 9.1, Cary, NC, USA).
RESULTS

Patient characteristics
The triple alkylator regimen BuCyMel was used in children undergoing allogeneic HSCT for AML in CR2. Patient characteristics are shown in Table 1 . Sixty patients (58% male, 42% female) reached CR2 with a median follow-up after diagnosis of first relapse of 3.4 years (0.3; 9.7). The median age at diagnosis of first relapse was 11.9 years (0.7; 18.3). Median age at HSCT was 12.2 years (0.9; 18.7). Median time between relapse and HSCT was 83.5 days (59; 85) in the case of a MSD, 105 days (75; 309) after MUD HSCT, and 117.5 days (74; 245) for those transplanted from a MMD.
Engraftment, toxicity and TRM Engraftment failure was reported in only 1/60 children. This child died from candida sepsis on day 41 after HSCT from a MMD. All other patients achieved engraftment. One of these developed secondary graft failure after an infectious episode.
Although severe complications such as hepatic sinusoid obstruction syndrome, hemorrhagic cystitis and CMV-reactivations were seen in some patients, the main reasons for TRM were GVHD and infection.
Sinusoid obstruction syndrome was reported in nine patients (MUD and MMD). Three of them finally died. Another three patients recovered completely and survived, whereas the remaining three experienced relapse from the underlying disease before symptoms of sinusoid obstruction syndrome had resolved.
All 19 patients reported with hemorrhagic cystitis completely recovered from it. CMV reactivation occurred in seven children, one of them died during blast crisis after experiencing a second relapse. All other patients became survivors after control of CMV reactivation.
The cumulative incidence of TRM was 12% (7/60, Figure 1 ). Causes of death were GVHD and/or infection in three patients, multi-organ failure not further specified in three patients, and sinusoid obstruction syndrome in one patient. All but one patient who died from TRM were transplanted from a MMD. GVHD aGVHD was graded 0-I and II-IV according to the criteria reported by Glucksberg et al.
7 Two-thirds showed no or a mild aGVHD (0-I), whereas 18 patients developed a more severe form of aGVHD (II-IV) (see Table 1 ). The incidence according to donor type of aGVHD (II-IV) was 0% (0/6) in MSD, 37% (11/30) in MUD and 29% (7/24) in MMD. cGVHD was reported in 13 patients. Of those, none was transplanted from a MSD, 7 were transplanted from a MMD, and 6 from a MUD. In 10/13 patients aGVHD proceeded cGVHD.
Relapse incidence
The cumulative incidence of relapse was 33 ± 4% at 5 years ( Figure 2 ). Eighteen out of sixty patients had a relapse at a median time of 142 days (84; 1548) after HSCT. Of those, 1 patient was transplanted from a MSD, 11 were transplanted from a MUD and 6 were transplanted from a MMD. Altogether, three patients could be salvaged after the second relapse, two by a second HSCT (follow-up after the second relapse is 2.0 and 5.6 years, respectively). The third achieved a third remission by intensive chemotherapy and donor lymphocyte infusions (fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG), maintenance therapy, follow-up: 3.9 years).
Survival and EFS
The OS in this retrospective cohort was estimated to be 62 ± 6% at 5 years ( Figure 3) . Thirty-eight patients survived in this high-risk patient group. EFS at 5 years was 55±7%, 35/60 patients remained in second CR with a median follow-up after HSCT of 3.68 years (0.3; 9.3). The EFS was not significantly higher for female patients, younger than 12 years at diagnosis of relapse and HSCT, and patients with a matched sibling of matched-unrelated donor. The OS did not differ significantly between the different donor types MSD, MUD and MMD. In multivariate analysis donor type, aGVHD, gender, cGVHD had no significant impact on OS, EFS and TRM (Table 2) . However, it is important to point out, that this piece of data must be considered to be descriptive as subgroups are too small for meaningful statistical analysis.
DISCUSSION
This retrospective interphase analysis was performed to evaluate the tolerability and anti-leukemic efficacy of the myeloablative preparative regimen consisting of BuCyMel. A triple alkylator regimen with a potentially significant toxicity was chosen in an effort to improve on the dismal prognosis of relapsed AML. None of the transplanted children had received HSCT during upfront treatment. We acknowledge that subgroups within this cohort are small making comparisons of statistical significance impossible. However, with a 5-year OS reaching 62% we demonstrate that there is hope for cure for the majority of children after relapse if an HLA-matched donor is available. TRM for the total group was 12%. A key issue of this report is the choice of a triple alkylator preparative regimen for a patient group that had undergone the complete first-line AML treatment followed by at least two induction and one consolidation course after relapse. As data from France suggest that a more intense conditioning regimen resulted in a better EFS with an acceptable increase in TRM, there is a strong argument in favor of intensifying the preparative regimen for patients undergoing HSCT in CR2. 9 Second, the Italian group (Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)) had presented data on employing BuCyMel for children with AML transplanted in CR1. In this series, TRM remained clear under 10%. 10 Third, the European prospective multi-center EWOG-MDS 98 trial had successfully started to recruit patients. Within this trial BuCyMel was used for conditioning of children with advanced myelodysplastic syndrome, which was based on Italian data published earlier. 11, 12 Taking BU/CY as a standard backbone, there is published experience with three other drugs that were added in an effort to escalate this regimen: thiotepa, 13 Where thiotepa and Mel are strongly myeloablative even as single agents, this is not the case for etoposide. [18] [19] [20] In the late 70's, etoposide was shown to be able to induce remission in 15-25% of patients with AML who had failed to remit after standard regimens used at that time. 21 These experiences led to the incorporation of this drug into the standard induction courses for newly diagnosed AML. Two groups have extrapolated these findings by adding etoposide to BU/CY for adult patients transplanted for AML in CR1. 15, 16 Reported TRM rates were 17-23% and 29%, relapse accounted for 19-23% and 24%, respectively. Thiotepa has been added to BU/CY mainly in the context of autologous high-dose regimens for myeloma. Its use for breast cancer in combination with other drugs has dramatically declined and its effectiveness for AML as to our knowledge has never been evaluated. Mel in contrast has been used for a variety of hematologic malignancies. Its profound stem-cell toxic properties make it a potentially attractive agent for malignancies whose origin is attributed to a hematopoietic stem cell defect such as in myelodysplastic syndrome (MDS) and AML, and, therefore, are difficult to cure with standard chemotherapy. 11, 22 In combination with BU, CY is most commonly dosed at 120 mg/kg. Higher doses used previously were associated with significantly higher toxicity. CY is a pro-drug that must be metabolized to its active compound in the liver. Although pharmacokinetics of the parent drug remains linear over a widedosing range, CY activation in the liver seems to reach its saturation at a dose of 100 mg/kg. 23 These results question the justification of higher CY doses, which might be even of greater importance, when a triple drug regimen is considered. Applying BU before CY enhances hepatic conversion to the active drug and increases toxicity. 24 Therefore, the application of CY should be delayed for at least 24 h after BU.
Most but not all children reported here received the i.v. formulation. In those who got oral BU, therapeutic drug monitoring was not consistently performed. The i.v. application of BU avoids the hepatic first-pass effect, thereby reducing the high local hepatic drug exposure. More recently, studies have been published demonstrating the feasibility of once daily dosing. Apart from being more convenient, pharmacokinetics were similar to conventional four-times-daily dosing. In addition, assuring a 24 h window before CY application has become much more manageable. 25, 26 The issues discussed above may be of great importance when we consider the choice of 'tools' to be used for children scheduled to receive HSCT. If we think that allogeneic HSCT is to be a treatment option reserved for children that experience AML relapse, what degree of toxicity are we willing to accept? Is it true that a more intensive conditioning reduces relapse rates after HSCT in CR2? Is it justified to use so called reduced intensity regimens trading a potentially higher relapse rate against lower treatment associated toxicity? If we retrospectively look at our interphase data and compare the outcome of children after BuCyMel in CR2 with those 49 children having received a preparative regimen consisting of something else, BuCyMel seems to be superior. OS is 62±6% vs 42±7% and relapse after HSCT was 33±7% and 35±7%, respectively. However, this is a retrospective 'as treated' analysis and results are certainly skewed by significant selection bias. There is only one way out of this dilemma: A prospective, controlled and if possible monitored multi-center trial with clearly defined stopping rules. Such a trial, AML SCT-BFM 2007, has now been initiated and is about to recruit children from 20 pediatric transplant centers in Germany, Austria, the Czech Republic and Switzerland. Log-Rank P = 0.57 Probability (95%)
Years after transplantation Figure 3 . OS at 5 years in pediatric AML patients transplanted in CR2 using BuCyMel as conditioning regimen. Analysis performed according to donor type.
